Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year.
Johnson & Johnson price target lowered to $160 from $166 at BofA
BofA analyst Tim Anderson lowered the firm’s price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares.